Cancers Treated:
About Kanwaldeep Mallhi
Biography:
My name is Dr. Kanwal Mallhi and I’m a pediatric hematologist/oncologist who specializes in hematopoietic stem cell transplantation and cellular therapies such as immunotherapy and gene therapy for children at Roswell Park Comprehensive Cancer Center.
My clinical expertise centers on cellular therapy treatments for high-risk hematologic malignancies and nonmalignant disorders, such as hemoglobinopathies, bone marrow failure syndromes, inherited inborn errors of metabolism, and primary immunodeficiency disorders. My goal is to expand access to curative therapies for children, adolescents and young adults with nonmalignant disorders and provide innovative treatments such as gene therapy for sickle cell disease, thalassemia and primary immunodeficiencies.
As part of my clinical research interests, I implement and manage stem cell transplant, gene therapy and cellular therapy clinical trials evaluating new targeted treatment options to improve curative outcomes for children with life-threatening malignant and nonmalignant disorders. My research interest focuses on providing patients with alternative stem cell donor options and efforts reducing transplant-related complications to improve patient outcomes.
Positions
- Associate Professor of Oncology
- Clinical Director of the Pediatric Transplantation and Cellular Therapy (TCT) Program
- Department of Pediatrics
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo
- Clinical Associate Professor of Pediatrics
Background
Education and Training:
- 2005-2009 - MD, Rosalind Franklin University of Medicine and Science, Chicago Medical School, Chicago, IL
- 2001-2005 - BSc- Molecular Biology and Biotechnology Major, McMaster University, Hamilton, Canada
Residency:
- 2009-2012 - Pediatrics, State University of New York at Buffalo, Buffalo, NY
Fellowship:
- 2015-2016 - Pediatric Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN
- 2012-2015 - Pediatric Hematology/Oncology, University of British Columbia, Vancouver, Canada
Board Certification:
- American Board of Pediatrics - General Pediatrics
- American Board of Pediatrics - Pediatric Hematology-Oncology
- Royal College of Physicians and Surgeons of Canada - Pediatrics
- Royal College of Physicians and Surgeons of Canada - Pediatric Hematology-Oncology
Professional Memberships:
- Children’s Oncology Group (COG)
- American Society of Pediatric Hematology and Oncology (ASPHO)
- American Society for Transplantation and Cellular Therapy (ASTCT)
- Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)
- American Society of Hematology (ASH)
- Primary Immune Deficiency Treatment Consortium (PIDTC)
- North American Pediatric Aplastic Anemia Consortium (NAPAAC)
- American Society for Gene and Cell Therapy (ASGCT)
Publications
1. Leiding JW, Arnold DE, Parikh SH, Logan BR, Marsh RA, Griffith LM, Wu R, Kidd S, Mallhi KK, Chellapandian D, Si Lim S, Grunebaum E, Falcone EL, Murguia-Favela L, Grossman D, Prasad VK, Heimall JR, Touzot F, Burroughs L, Bleesing J, Kapoor N, Dara J, Williams O, Kapadia M, Oshrine BR, Bednarski JJ, Rayes A, Chong H, Cuvelier GDE, Forbes Satter LR, Martinez C, Vander Lugt MT, Yu LC, Chandrakasan S, Joshi A, Prockop SE, Dávila Saldaña BJ, Aquino V, Broglie L, Ebens CL, Madden LM, DeSantes K, Milner J, Rangarajan HG, Shah A, Gilio AP, Knutsen AP, Miller HK, Moore TB, Graham P, Bauchat A, Bunin NJ, Teira P, Petrovic A, Chandra S, Abdel-Azim H, Dorsey M, Birbrayer O, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Malech HL, Kang EM. “Genotype, Oxidase Status, and Preceding Infection or Autoinflammation Do Not Affect Allogeneic HCT Outcomes for CGD.” Blood. 2023 Aug 10;. doi: 10.1182/blood.2022019586. PubMed PMID: 37562003.
2. DeZern A, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg J, Leifer E, Brodsky RA, Logan BR, Pulsipher MA. “Haploidentical Donor Bone Marrow Transplantation in Relapsed or Refractory Severe Aplastic Anemia in the USA (BMT CNT 1502): A Multicenter, Single Arm, Phase 2 Trial”. Lancet Hematology. 2022 July 27. doi.org/10.1016/S2352-3026(22)00206-X. PMID: 35907408.
3. Mallhi KK, Srikanthan MA, Baker KK, Frangoul HA, Torgerson TR., Petrovic A, Geddis AE, Carpenter PA, Baker KS, Sandmaier BM., Thakar MS, Skoda-Smith S, Kiem HP, Storb R, Woolfrey AE, Burroughs LM. “HLA-Haploidentical Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide.” Biology of Blood Marrow Transplant. 2020 Jul; 26(7):1332-1341. doi: 10.1016/j.bbmt.2020.03.018. PMID: 32234377.
4. Dahlberg A, Leisenring W, Bleakley M, Meshinchi S, Baker KS, Summers C, Hadland B, Delaney C, Mallhi K, Burroughs L, Carpenter P, Woolfrey A. Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children. Bone Marrow Transplant. 2019 Aug;54(8):1337-1345. doi: 10.1038/s41409-019-0438-z. Epub 2019 Jan 22. PubMed PMID: 30670822; PubMed Central PMCID: PMC6646113.
5. Mallhi K, Orchard PJ, Miller WP, Cao Q, Tolar J, Lund TC. Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature. Bone Marrow Transplant. 2017 May;52(5):726-732. doi: 10.1038/bmt.2016.356. Epub 2017 Jan 16. PubMed PMID: 28092353; PubMed Central PMCID: PMC5604220.